Hormone FDA Approved

Dasiglucagon

A glucagon analog approved in the United States as Zegalogue for severe hypoglycemia.

Glucagon AnalogFDA ApprovedHypoglycemiaMetabolic

Also referenced as: Zegalogue

Public product evidence No certificate records are bound to a tracked Dasiglucagon product page A record counts here only when a vendor publishes a certificate against one of its own tracked Dasiglucagon product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area
Hormone signaling research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems
Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
1

Zegalogue

Signal depth
High

FDA label signal · 21 trials · 47 PubMed results

Established
Research evidence

Dasiglucagon is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Dasiglucagon has 16 name-matched clinical trials (highest phase: Phase 3) and 47 PubMed-indexed publications and holds an FDA drug label. 7 trials have posted results.

FAERS (approved drug): 5
Human data
Approved drug
Trial quality
Randomized
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
High-impact
PHASE3 · Randomized A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects PHASE3 · Randomized A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus PHASE3 · Randomized A Trial to Compare the Efficacy and Safety of 2 Different Batches of Subcutaneous Dasiglucagon in Patients With T1DM Diabetes Care · 114 citations Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog Diabetes Care · 74 citations Performance of the Insulin-Only iLet Bionic Pancreas and the Bihormonal iLet Using Dasiglucagon in Adults With Type 1 Diabetes in a Home-Use Setting Diabetes Care · 53 citations Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What dasiglucagon is

Dasiglucagon is a glucagon analog approved in the United States as Zegalogue.

Why it matters

It adds a very real peptide-drug example from metabolic medicine and helps balance a library that can otherwise skew too heavily toward weight-loss signaling alone.

Regulatory context

Dasiglucagon is FDA approved in the United States.

Practical reading note

Approved glucagon-pathway drugs deserve a place in the library because they show how broad peptide pharmacology actually is in clinical medicine.